Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School. The projects, which target a diverse range of conditions—type 1 diabetes, asthma, frontotemporal dementia, deadly cancer-associated blood clots and a rare congenital immune disease—will each receive $1 million over two years to advance their efforts. Awardees will also receive active support and guidance from the HMS Translator, a recently launched program to advance drug discovery efforts at HMS. Read the full article, "Investing in Exceptional Promise," Kevin Jiang, October 29, 2020 Research Awards and Achievements HMS Community.